Cargando…
Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders
The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulato...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104141/ https://www.ncbi.nlm.nih.gov/pubmed/35563156 http://dx.doi.org/10.3390/ijms23094764 |
_version_ | 1784707722293280768 |
---|---|
author | Navarro, Daniela Gasparyan, Ani Navarrete, Francisco Torregrosa, Abraham B. Rubio, Gabriel Marín-Mayor, Marta Acosta, Gabriela B. Garcia-Gutiérrez, Maria Salud Manzanares, Jorge |
author_facet | Navarro, Daniela Gasparyan, Ani Navarrete, Francisco Torregrosa, Abraham B. Rubio, Gabriel Marín-Mayor, Marta Acosta, Gabriela B. Garcia-Gutiérrez, Maria Salud Manzanares, Jorge |
author_sort | Navarro, Daniela |
collection | PubMed |
description | The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry. |
format | Online Article Text |
id | pubmed-9104141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-91041412022-05-14 Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders Navarro, Daniela Gasparyan, Ani Navarrete, Francisco Torregrosa, Abraham B. Rubio, Gabriel Marín-Mayor, Marta Acosta, Gabriela B. Garcia-Gutiérrez, Maria Salud Manzanares, Jorge Int J Mol Sci Review The therapeutic benefits of the current medications for patients with psychiatric disorders contrast with a great variety of adverse effects. The endocannabinoid system (ECS) components have gained high interest as potential new targets for treating psychiatry diseases because of their neuromodulator role, which is essential to understanding the regulation of many brain functions. This article reviewed the molecular alterations in ECS occurring in different psychiatric conditions. The methods used to identify alterations in the ECS were also described. We used a translational approach. The animal models reproducing some behavioral and/or neurochemical aspects of psychiatric disorders and the molecular alterations in clinical studies in post-mortem brain tissue or peripheral tissues were analyzed. This article reviewed the most relevant ECS changes in prevalent psychiatric diseases such as mood disorders, schizophrenia, autism, attentional deficit, eating disorders (ED), and addiction. The review concludes that clinical research studies are urgently needed for two different purposes: (1) To identify alterations of the ECS components potentially useful as new biomarkers relating to a specific disease or condition, and (2) to design new therapeutic targets based on the specific alterations found to improve the pharmacological treatment in psychiatry. MDPI 2022-04-26 /pmc/articles/PMC9104141/ /pubmed/35563156 http://dx.doi.org/10.3390/ijms23094764 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Navarro, Daniela Gasparyan, Ani Navarrete, Francisco Torregrosa, Abraham B. Rubio, Gabriel Marín-Mayor, Marta Acosta, Gabriela B. Garcia-Gutiérrez, Maria Salud Manzanares, Jorge Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
title | Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
title_full | Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
title_fullStr | Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
title_full_unstemmed | Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
title_short | Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders |
title_sort | molecular alterations of the endocannabinoid system in psychiatric disorders |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9104141/ https://www.ncbi.nlm.nih.gov/pubmed/35563156 http://dx.doi.org/10.3390/ijms23094764 |
work_keys_str_mv | AT navarrodaniela molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders AT gasparyanani molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders AT navarretefrancisco molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders AT torregrosaabrahamb molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders AT rubiogabriel molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders AT marinmayormarta molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders AT acostagabrielab molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders AT garciagutierrezmariasalud molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders AT manzanaresjorge molecularalterationsoftheendocannabinoidsysteminpsychiatricdisorders |